Skip to main content
SpringerLink
Log in

Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors

  • Research Letter
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ruiz JN, Belum VR, Creel P, et al. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. Clin Genitourin Cancer. 2014;12(5):341–7. https://doi.org/10.1016/j.clgc.2014.04.001 (Epub 2014 May 16. PMID: 25035283; PMCID: PMC4181324).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lacouture ME, Basti S, Patel J, Benson A 3rd. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol. 2006;4(5):236–8.

    PubMed  Google Scholar 

  3. Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011;65(3):624–35. https://doi.org/10.1016/j.jaad.2010.06.051.

    Article  PubMed  Google Scholar 

  4. Barrios DM, Phillips GS, Freites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340–7. https://doi.org/10.1111/jdv.16159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Thompson LL, Li EB, Krasnow NA, et al. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br J Dermatol. 2021;185(3):627–35. https://doi.org/10.1111/bjd.20074.

    Article  CAS  PubMed  Google Scholar 

  6. Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center. JAMA Dermatol. 2020;156(10):1079–85. https://doi.org/10.1001/jamadermatol.2020.1795.

    Article  PubMed  Google Scholar 

  7. Rossi AM, Hibler BP, Navarrete-Dechent C, Lacouture ME. Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies. J Am Acad Dermatol. 2021;85(3):693–707. https://doi.org/10.1016/j.jaad.2020.08.005.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 East 74th Street, New York, NY, 10021, USA

    Alexander S. Bang, Alina Markova, Allison Gordon, Anthony M. Rossi, Sarah J. Noor & Mario E. Lacouture

  2. Division of Dermatology, Washington University School of Medicine, St. Louis, MO, USA

    Milan J. Anadkat

  3. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Jennifer N. Choi

  4. Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA

    Nicole R. LeBoeuf

  5. Norton Cancer Institute, Louisville, KY, USA

    Jae Y. Jung

  6. Department of Oncodermatology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

    Vincent Sibaud

Authors
  1. Alexander S. Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Milan J. Anadkat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer N. Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicole R. LeBoeuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae Y. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alina Markova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Allison Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anthony M. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sarah J. Noor
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vincent Sibaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mario E. Lacouture
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario E. Lacouture.

Ethics declarations

Funding

No external funding was used in the preparation of this letter.

Conflict of interest

Dr. Anadkat has served as a consultant for ImClone, Bristol Myers Squibb, AstraZeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli Lilly, Abbvie, Boehringer-Ingelheim, Innovaderm, UCB Biopharma, Novocure, OnQuality, and Springworks. Dr. Anadkat has served as a Principal Investigator for Novartis, Boehringer-Ingelheim, Lutris, OnQuality, UCB Biopharma, InflamRx, Eli Lilly, InCyte, Abbvie, AnaptysBio, Hana Biosciences, Xoma, Veloce, Biogen, Xbiotech, and Chemocentryx. Dr. Choi has a consultant role with OnQuality, Regeneron, Parexel, Azitra, La Roche-Posay Pharmaceuticals, and PraHealthSciences. Dr. Choi has served as a consultant for Biotest AG, Keratin Biosciences, Bristol Meyers Squibb, Novartis, Array Biopharma, and Kyowa Kirin International. Dr. Choi has served as a Principal Investigator for OnQuality, InCyte, and Veloce. Dr. Jung has a consultant role at Regeneron and Sanofi. Dr. Lacouture has a consultant role with Oncoderm Labs, Johnson and Johnson, Novocure, QED, Bicara, Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, AstraZeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Azitra, Roche, Oncoderm, NCODA, and Apricity. Dr. Lacouture also receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis, National Institutes of Health, and AstraZeneca. Dr. LeBoeuf is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback, and Synox Therapeutics. Dr. Markova has a consultant role with Alira Health and Blueprint Medicines, and receives research funding from Amryt Pharma and Incyte Corp. Dr. Noor has a consultant role with Kyowa Kirin. Dr. Sibaud has received consulting fees from Amgen, Bristol Myers Squibb, Pierre Fabre, and Bayer. Dr. Sibaud has received honoraria for lectures from Bristol Myers Squibb, Pierre Fabre, Novartis, and Incyte. Dr. Sibaud participates on a data safety monitoring board for Bristol Myers Squibb. Dr. Rossi has served as a consultant for Almirall, Mavig, Dynamed, Canfield Scientific, Allergan Inc., Biofrontera, MD, Lam Therapeutics, Regeneron, Cutera, Skinfix, and L’Oreal. Dr. Rossi has received research funding from Regen, LeoPharma, and Biofrontera. Dr. Rossi serves on the editorial boards for Lasers in Surgery and Medicine, Cutis, Journal of the American Academy of Dermatology, and Dermatologic Surgery. Alexander Bang and Dr. Gordon have no conflicts of interest that might be directly relevant to the contents of this letter.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable

Availability of data and material

Data of the supporting information are available upon request from the authors and a directory of oncodermatologists is available from oncodermatologysociety.org.

Code availability

Not applicable.

Authors’ contributions

Conception and design: ASB and MEL. Acquisition of data: ASB and MEL. Analysis and interpretation of data: ASB, MJB, JNN, NRL, JYJ, AM, AG, AMM, SJN, VS, and MEL. Critical revision of the manuscript: ASB, MJB, JNN, NRL, JYJ, AM, AG, AMM, SJN, VS, and MEL.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 236 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bang, A.S., Anadkat, M.J., Choi, J.N. et al. Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors. Am J Clin Dermatol 23, 587–589 (2022). https://doi.org/10.1007/s40257-022-00705-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-022-00705-z

Search

Navigation